Lessons from the ANTES B+ study
enero 14, 2026
Lessons from the ANTES B+ study highlighting challenges in COPD clinical trials, recruitment difficulties, and implications for future study design.
Lessons from the ANTES B+ study highlighting challenges in COPD clinical trials, recruitment difficulties, and implications for future study design.
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
Discover how ex vivo lung perfusion (EVLP) impacts the lung microbiome and its implications for improving donor lung viability and reducing transplant complications.
No te pierdas la II edición RESPrimaria el próximo 7 de mayo. Inscríbete en formato Streaming o solicita tu invitación presencial. ¡Plazas limitadas!
Protocolised treatable trait-based asthma management was acceptable to patients not under the care of a severe asthma clinic, associated with significant clinical benefit, and a full trial appears feasible.
Descubre los avances en el diagnóstico y tratamiento de la EPOC con el Dr. Alvar Agustí en la II Jornada SEMG Resprimaria. Conoce la importancia de la espirometría, la detección precoz y las nuevas estrategias terapéuticas.